• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Disease Modifying Anti-Rheumatic Drugs
    29 Drugs classified under this therapeutic system


    All the Therapeutic System Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Abitrexate
    Salomon, Levin & Elstein Ltd
    RX
    partial basket chart
    Abitrexate

    Folic Acid Analog. Methotrexate 25 mg/ml.
    VIAL (sol. for inj.): 25 mg/ ml X 2 ml, 4 ml,
    8 ml, 20 ml, 40 ml. Dose must be ajust.
    individ. for each pt. accord. to med.
    cond. See lit.
    Antineopl. Chemother.
    Tmt. of gestational choriocarcinoma,
    chorioadenoma destruens and
    hydatidiform mole. Palliation of ALL. Tmt.
    and proph. of menin. leukemia.
    Greatest effect has been observed in
    palliation of acute lymphoblast.(stemcell)
    leukemias in child. In comb. with
    other anticancer agents, may be used for
    the induc. of remis.,but is most common.
    used in the mainten. of induced remis.
    May be used alone, or in comb. with other
    antineoplastic drugs, in the manag. of
    breast canc., epidermoid cancers of the
    head and neck, lung cancer (partic.
    squamous cell ,small cell types), bladder
    cancer and osteogenic cancer. Tmt. of the
    advan.stages (III and IV, Peter’s Staging
    system) of lymphosarcoma, partic. in
    child., and in advanced cases of mycosis
    fungoides.
    Psoriasis. Indic. only in the sympt. control
    of sev. recalcitrant, disabling psoriasis
    which is not adeq. responsive to other
    forms of therapy, and only when the diag.
    has been established, as by biopsy and/or
    after dermat. consult. RA:Tmt. of selec.
    adul.with sev. RA, only when the diag. has
    been well established accord. to rheumat.
    standards, with inadeq. response to other
    forms of antirheum. ther., includ. full dose
    NSAIDs and usually a trial of at least one
    or more dis.-modif. antirheum. drugs.
    C/I: Pregnancy, lact., pts. in poor state of
    nutrition, sev. ren. impair. (crCL <20 ml/
    min), sev. liver impair., bone marrow
    hypoplasia, leucopenia,
    thrombocytopenia, anemia, alcohol
    abuse, hypersens. and lung toxic.due to
    methotrexate, serious, acute or chronic
    infect. such as tuberculosis and HIV,
    ulcers of the oral cavity and known
    active GI ulcer dis. Concur. vaccin. with
    live vaccines.

    Actemra
    Roche
    RX
    partial basket chart
    Actemra

    Interleukin-6 Receptor Inhibitor. Tocilizumab 20 mg/ml.
    VIALS: 1, 4 x 80 mg/4 ml; 200mg/10 ml;
    400 mg/20 ml.
    RA : 8mg/kg bdy wt. I.V. 1 x every 4
    weeks.
    Pts. bdy wt. > 100 kg, dose exceed. 800
    mg/infus. not recommend. See lit. SJIA:
    <30 kg bdywt: 12 mg/kg bdywt, every
    2 wks; ≥30 kg bdywt: 8 mg/kg bdywt,
    every 2 wks.
    Reduce signs/sympts. in adult pts with
    mod-severe active rheum. arthrit. when
    inad. response to one/more DMARDS or
    TNF antags., or in pts unable to use
    DMARDs. Can be used alone/in comb. with
    methotrexate/other DMARDs. Reduce rate
    progress. joint damage as measured by
    X-ray, improve physic. funct. when in
    combinat. methotrexate. Tmt. active
    system. juv. idiopath. arthrit. in pts. > 2 yrs.
    C/I: Hypersens., active severe infects.

    Actemra 162 mg S.C.
    Roche
    RX
    partial basket chart
    Actemra 162 mg S.C.

    Interleukin-6 Receptor Inhibitor. Tocilizumab 162 mg / 0.9 ml.
    PRE- FILLED SYRINGE.: 4 x 162 mg/0.9 ml
    Inj. S.C. 162 mg once a week.
    In comb. with MTX, for the tmt. of moder.-
    severe active RA in adult pt. who have
    either responded inadequate. to, or who
    were intoler. to, prev. therapy with one or
    more DMARDs or TNF antagonists. In
    these pts., Tocilizumab can be given as
    monother. in case of intolerance to MTX or
    where continued tmt. with MTX is
    inappropriate.
    C/I: Hypersens., active severe infects.

    AMGEVITA
    Amgen
    RX
    not in the basket chart
    AMGEVITA

    TNF Blocking Agent. Adalimumab 50 mg/ml..
    PRE-FILLED SYRINGE: 2 ×(20 mg/0.4 mL, 40mg/0.8ml)
    PRE-FILLED PEN: 2× (40mg /0.8 ml).
    Dosage ajust. individ. accord. to pt. med. condit.
    RA: in comb. with methotrexate-tmt. of moder.-sev., active RA in adult pts. when the response to dis.-modif. anti-rheumat.drugs includ. methotrexate has been inadequate.
    The tmt. of sev., active and progres. RA  in adult.not previous. treated with methotrexate,  given as monother. in case of intolerance to methotrexate or when continued tmt. with methotrexate is inappropr. AMGEVITA has been shown to reduce the rate of progress. of joint damage as measured by X-ray and to improve physical funct., when given in comb. with methotrexate.
    Axial spondyloarthritis Ankylosing spond. (AS): tmt. of adult. with severe active AS who have had an inadeq. response to convent. ther.
    Axial spondyloarthritis without radiograph. evidence of AS: tmt. of adults with sev. axial spondyloarthritis without radiograph.evidence of AS, but with object. signs of inflamm. by radiolog. and/or lab. tests includ. MRI and serum CRP levels, who have had an inadequate response to, or are intoler, to,NSAID’s.
    Psoriatic arthritis: tmt. of active and progress. psoriat. arthritis in adults when the response to previous dis.-modif. anti-rheum.drug ther. has been inadequate. Adalimumab has been shown to reduce the rate of progress. of peripher. joint damage as measured by X-ray in pts. with polyarticular symmetr. subtypes of the dis. and to improve physic. func.
    Psoriasis: tmt. of moder.-sev. chron. plaque psoriasis in adult pts. who are candidates for system. ther.
    Hidradenitis suppurativa (HS): tmt. of active moder.- sev. hidradenitis suppurativa (acne inversa) in adult pts. with an inadequate response to convent. system. HS ther.
    Crohn’s dis. : reducing signs and sympt.and induc.and maintain. clinical remiss. in adult pts. with moder.- sev. active Crohn’s dis. who have had an inadequate response to convent. ther. AMGEVITA is indic. for reduc. signs and sympt. and induc. clinical remiss. in these pts. if they have also lost response to or are intoler. to infliximab.
    Ulcerat. colit.: tmt. of moder.-sev. active ulcerat. colit. in adult pts. who have had an inadequate response to convent. ther. includ. corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intoler. to or have med. contraindicat. for such therapies.
    Uveitis : tmt. of non-infect. intermed., posterior and panuveitis in adult pts. who have had an inadequate response to corticosteroids, in pts. in need of corticosteroid-sparing, or in whom corticosteroid tmt. is inappropr.
    Intestinal Behcet's dis.:  tmt. of intestin. Behcet’s dis. in pts. who have had an inadequate response to convention. ther.

    C/I: Hypersens.
    Active tuberculosis or other sev. infect. such as sepsis, and opportunist.infec.
    Moder.-sev. HF(NYHA class III/IV).

    Benlysta 120 mg, 400 mg
    GSK
    RX
    partial basket chart
    Benlysta 120 mg, 400 mg

    Monoclonal Antibody. Belimumab 120 mg, 400 mg.
    VIAL (pwdr. for concentrate for sol. for infus.): 1×120mg.
    VIAL (pwdr. for concentrate for sol. for infus.): 1×400mg.
    Benlysta 120,400 mg: Premed. includ. an antihistamine, with/without an antipyretic, may be admin. before the  infus. The recomm. dose is 10 mg/kg on Days 0, 14 and 28, and at 4-wk. interv. thereafter. The patient’s condition should be evaluated continuous. Discont. of tmt. should be consid. if there is no improve. in dis. control after 6 mnths. of tmt. See lit.
    Indic. as add-on ther. in adult pts. with active, autoantibody-posit. system. lupus erythematosus (SLE) with a high degree of dis. activity (e.g., positive anti-dsDNA and low complement) despite standard ther.
    C/I: Hypersens.

    Benlysta 200 mg
    GSK
    RX
    partial basket chart
    Benlysta 200 mg

    Monoclonal Antibody. Belimumab 200 mg.
    PRE-FILL. PEN (sol. for S.C. inj.): 1, 4×200mg/ml.
    PRE-FILL.SYR. (sol. for S.C. inj.): 1, 4×200mg/ml.
    Benlysta 200mg/ml: 200 mg once wkly., admin. S.C. dosing is not based on weight.
    The pt’s. condition should be evaluat. continuous. Discont. of tmt. should be consid. if there is no improv. in dis.  control after 6 mnths. of tmt.
    If a dose is missed, it should be admin. as soon as possible. Thereafter, pts. can resume dosing on their usual day of admin., or start a new wkly.
    Transit. from IV to S.C. admin.: If a pt. is being transitioned from IV admin. to S.C. admin., the 1st S.C. inj. should be admin. 1-4 wks. after the last IV dose. See lit.
    Indic. as add-on ther. in adult pts. with active, autoantibody-posit. system. lupus erythematosus (SLE) with a high degree of dis. activity (e.g., positive anti-dsDNA and low complement) despite standard ther.
    C/I: Hypersens.


    Other therapeutic systems under Musculo-Skeletal Disorders

    CLOSE